Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
CARMIEL, Israel, Feb. 22, 2016 -- Protalix BioTherapeutics, Inc. (NYSE:PLX) and (TASE:PLX), announced today that the Company will participate in the SunTrust Robinson Humphrey Orphan Drug Day and the 12th Annual WORLDSymposiumTM 2016. The details are as follows:
SunTrust Robison Humphrey Orphan Drug Day
February 23, 2016
JW Marriott Essex House, New York City, NY
12th Annual WORLDSymposiumTM 2016
February 29 – March 4, 2016
Manchester Grand Hyatt, San Diego, CA
Oral presentation: “Novel treatment for Fabry disease: IV administration of plant derived alpha-GAL-A enzyme safety and efficacy interim report,” to be presented by Dr. Derralynn Hughes of the Lysosomal Storage Disease Unit, Institute of Immunity and Transplantation, Royal Free London NHS Foundation Trust, London, UK, and a principal investigator in the Company’s clinical trial of PRX-102 for the treatment of Fabry disease. The oral presentation will be given at 3:15 PM PT on Thursday, March 3, 2016.
Poster #138: “PRX-102 α-Galactosidase-A (peguniglasidase alfa) -- Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease.”
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. Protalix's development pipeline includes the following product candidates: PRX-102, a pegylated version of a recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-106, an orally-delivered anti-inflammatory treatment; PRX-110, a chemically modified DNase I for the treatment of Cystic Fibrosis; and others.
Investor Contact Marcy Nanus The Trout Group, LLC 646-378-2927 [email protected]
